Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28102974 | 0.95 | LMNA (0.44) | LMNAHRH4HRH3DRD1TAAR1 | |
| SCHEMBL29015942 | 0.80 | SMYD2 (0.36) | — | |
| SCHEMBL28201268 | 0.80 | TSHR (0.39) | LMNATSHR | |
| SCHEMBL27818446 | 0.80 | LMNA (0.43) | LMNAHRH4HRH3DRD1TAAR1 | |
| SCHEMBL28636592 | 0.79 | LMNA (0.42) | LMNAHRH4HRH3DRD1TAAR1 | |
| SCHEMBL28621831 | 0.78 | LMNA (0.44) | LMNAHRH4HRH3DRD1TAAR1 | |
| SCHEMBL28636591 | 0.78 | LMNA (0.41) | LMNAHRH4HRH3DRD1TAAR1 | |
| SCHEMBL29121137 | 0.77 | LMNA (0.39) | LMNAHRH4HRH3PTPN1CDC25B | |
| SCHEMBL28802201 | 0.76 | LMNA (0.47) | LMNAHRH4HRH3DRD1TAAR1 | |
| SCHEMBL524359 | 0.76 | LMNA (0.47) | LMNAHRH4HRH3DRD1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117677399-A | Effective ASGPR binding compounds for the degradation of immunoglobulins and other proteins | 阿维拉治疗公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117222414-A | Compounds for activating constant natural killer T-cells and methods for eliminating inflammatory senescent cells | 脱落性治疗公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-109963870-B | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116284404-A | anti-B7-H3 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116173232-A | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-116059201-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059202-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116059394-A | anti-EGFR antibody drug conjugates | 艾伯维公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115885042-A | Double-stranded oligonucleotide compositions and methods related thereto | 波涛生命科学有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-109562170-B | anti-CD 98 antibodies and antibody drug conjugates | 艾伯维公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-115427049-A | Inhibitors of malaria and plasmodium falciparum hexose transporters and uses thereof | 清华大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-111620861-A | BCL-XL inhibitory compound having low cell permeability and antibody drug conjugate including the same | 艾伯维公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2020040433-A1 | METHOD FOR PREPARATION OF SGLT-2 INHIBITOR, DAPAGLIFLOZIN PRECURSOR | 동아에스티 주식회사 | 2020-02-27 | — | — | WO | disclosed |